First-in-history drug approvals now arrive in waves, not once per generation.
Within a single month the FDA cleared the first-ever drug for ataxia-telangiectasia, the first nephrotic-syndrome option in 70 years, the first type-1-diabetes kidney-disease therapy in three decades, and a third FOP drug in three years — repurposed antibodies, precision inhibitors, and gene therapy are emptying the no-approved-therapy list in batches.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Another population with zero approved options is served within the same unprecedented approval season.
A never-before-approved device category cleared within the same season's batch of historic firsts, extending the wave beyond drugs.
A disease emptying its no-therapy list in three years is the approval wave operating at full speed.
A seven-decade treatment vacuum closes, completing the wave of firsts the theme predicts.
A condition with zero approved therapies gains its first-ever drug, adding to the month's batch of first-in-history clearances.
Another decades-long therapeutic vacuum closed within the same approval wave rather than once in a generation.
The finding itself situates the MCT8 first inside an accelerating wave of first-in-history clearances rather than a once-per-generation event.
A first-of-its-kind helicase-primase approval ends a four-decade mechanism monopoly, joining the current wave of unprecedented first-ever clearances.
A uniformly fatal neurodegenerative disease with zero approved treatments anywhere gets its first drug inside the same season's wave of first-ever clearances.